Message #55 From:
NewsBot Date: February 28, 2007 04:00:00 AM
DEPO News Depomed to Announce Fourth Quarter and Year End 2006 Financial Results on Wednesday, March 14
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter and year end financial results for 2006 after the market closes on Wednesday, March 14, 2007. The company will webcast a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results and to provide an update and future outlook on company events.
Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm™ drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin® XR (ciprofloxacin hydrochloride) extended-release tablets have been approved by the FDA for the once daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once daily Glumetza™ (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is currently being marketed in the United States and Canada. The company is conducting a Phase 3 trial in postherpetic neuralgia and has completed a Phase 2 trial in diabetic peripheral neuropathy with its product candidate, Gabapentin GR™. Additional information about Depomed may be found at its web site, www.depomedinc.com.
